Episode 3 – MS treatment landscape part two: potential role of biosimilars
01 września 2025
In the third episode of the Illuminoz podcast series, Sim Trivedy speaks with Dr. David Paling – UK-based neurologist and director of the MS Academy – about how biosimilars could help address unmet needs in multiple sclerosis care.
Can lower-cost therapies improve access to high-efficacy treatments? What changes in reimbursement and value-based care could benefit patients? And how might biosimilars support the long-term sustainability of healthcare systems?
Tune in to hear expert insights on how biosimilars could reshape MS treatment—making it more accessible, efficient, and future-ready.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
dr Laura Airas,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
